At SCIRENT, we support our Medtech and Biopharmaceutical clients in designing and executing early-phase cardiovascular trials with precision and care. Phase I studies typically involve a small group of healthy volunteers or stable patients to assess safety, tolerability, and pharmacokinetics. They are the first stage where a new drug or device is tested in humans. These trials primarily focus on safety, tolerability, and pharmacokinetics.
Conducted in a highly controlled environment, Phase I trials assess how the investigational product is absorbed, distributed, metabolized, and excreted. Dose-escalation protocols help determine the maximum tolerated dose while monitoring for adverse events and early signs of benefit.
We help you generate the early evidence needed to guide investment and development decisions with confidence.
We are a specialized cardiovascular CRO with a deep understanding of the regulatory, clinical, and operational landscape. Whether you’re developing a novel device, diagnostic, or drug – we bring the expertise, network, and flexibility you need at every stage of development.
How can we help you? We will get in touch shortly.
